Bionano Genomics reported second quarter 2026 financial results with total revenue of $8.2 million, a 21% increase from the prior year period. Consumables revenue rose 31% to $4.3 million, driven by increased clinical adoption and utilization. The company sold 9,219 nanochannel array flow cells, up 27% year-over-year, and generated a gross margin of 53%. Operating expenses were $11.5 million, while adjusted operating expenses decreased to $8.7 million. Bionano also announced the full retirement of its outstanding secured convertible debentures, eliminating all secured debt obligations. Additionally, Dr. Alex Hastie was appointed Chief Scientific Officer. The company provided Q3 2026 revenue guidance between $8.2 and $8.6 million and full-year 2026 revenue guidance between $31 and $33 million. Bionano Genomics operates in the biotechnology industry, providing optical genome mapping solutions for genomic analysis.

Bionano Genomics, Inc. announced the appointment of Alex Hastie, Ph.D. as the new Chief Scientific Officer, effective July 20, 2026. The company operates in the life sciences industry, providing genomic mapping technology and software solutions.